BRPI0510848A - derivados de pirrolotriazina úteis para o tratamento de distúrbios e doenças hiperproliferativos associados com a angiogênese - Google Patents

derivados de pirrolotriazina úteis para o tratamento de distúrbios e doenças hiperproliferativos associados com a angiogênese

Info

Publication number
BRPI0510848A
BRPI0510848A BRPI0510848-9A BRPI0510848A BRPI0510848A BR PI0510848 A BRPI0510848 A BR PI0510848A BR PI0510848 A BRPI0510848 A BR PI0510848A BR PI0510848 A BRPI0510848 A BR PI0510848A
Authority
BR
Brazil
Prior art keywords
angiogenesis
treatment
diseases associated
derivatives useful
hyperproliferative disorders
Prior art date
Application number
BRPI0510848-9A
Other languages
English (en)
Inventor
Julie A Dixon
Catherine Brennan
Karl Miranda
Brent Chandler
Barton Phillips
Jianmei Fan
Michael Brands
Andrea Mcclure
Benjamin Jones
Wenlang Fu
Donald Bierer
Steven Magnuson
Harold C E Kluender
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971944&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0510848(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of BRPI0510848A publication Critical patent/BRPI0510848A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DERIVADOS DE PIRROLOTRIAZINA úTEIS PARA O TRATAMENTO DE DISTúRBIOS E DOENçAS HIPERPROLIFERATIVOS ASSOCIADOS COM A ANGIOGêNESE. Esta invenção relaciona-se aos novos compostos de pirrozolotriazina, às composições farmacêuticas que contêm tais compostos e ao uso destes compostos e composições para a prevenção e/ou o tratamento de distúrbios e doenças hiperproliferativos, associados com a angiogênese.
BRPI0510848-9A 2004-06-03 2005-06-03 derivados de pirrolotriazina úteis para o tratamento de distúrbios e doenças hiperproliferativos associados com a angiogênese BRPI0510848A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57665204P 2004-06-03 2004-06-03
US62653104P 2004-11-09 2004-11-09
PCT/US2005/019472 WO2005121147A1 (en) 2004-06-03 2005-06-03 Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Publications (1)

Publication Number Publication Date
BRPI0510848A true BRPI0510848A (pt) 2007-11-27

Family

ID=34971944

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510848-9A BRPI0510848A (pt) 2004-06-03 2005-06-03 derivados de pirrolotriazina úteis para o tratamento de distúrbios e doenças hiperproliferativos associados com a angiogênese

Country Status (31)

Country Link
US (3) US7563791B2 (pt)
EP (1) EP1765823B1 (pt)
JP (1) JP4958772B2 (pt)
KR (1) KR101235602B1 (pt)
CN (1) CN1993361B (pt)
AR (1) AR049138A1 (pt)
AT (1) ATE462708T1 (pt)
AU (1) AU2005252217B2 (pt)
BR (1) BRPI0510848A (pt)
CA (1) CA2569396C (pt)
DE (1) DE602005020293D1 (pt)
EC (1) ECSP067043A (pt)
ES (1) ES2342722T3 (pt)
GT (1) GT200500137A (pt)
HK (1) HK1109141A1 (pt)
HN (1) HN2005000255A (pt)
IL (1) IL179264A0 (pt)
MA (1) MA28689B1 (pt)
MX (1) MX279139B (pt)
MY (1) MY145077A (pt)
NO (1) NO20070049L (pt)
NZ (1) NZ551742A (pt)
PE (1) PE20060243A1 (pt)
PH (1) PH12006502386B1 (pt)
RU (1) RU2401269C2 (pt)
SG (1) SG127661A1 (pt)
SV (1) SV2006002134A (pt)
TW (1) TW200608979A (pt)
UY (1) UY28931A1 (pt)
WO (1) WO2005121147A1 (pt)
ZA (1) ZA200700011B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2007064931A2 (en) * 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CA2634047C (en) 2005-12-21 2016-04-12 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
EP1882475A1 (en) * 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
US7912582B1 (en) * 2007-05-03 2011-03-22 Innovation Associates, Inc. Robotic prescription filling system
CA2698795C (en) 2007-09-10 2016-04-19 Cipla Limited Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
EP2203060A4 (en) * 2007-09-25 2010-12-22 Bayer Healthcare Llc PYRROLOTRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER BY INHIBITING AURORA KINASE
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
EP2739144A4 (en) * 2011-06-20 2015-04-01 Alzheimer S Inst Of America Inc COMPOUNDS AND ITS THERAPEUTIC USE
CA2840518A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
WO2013087647A1 (en) 2011-12-15 2013-06-20 Bayer Intellectual Property Gmbh Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer
US9475815B2 (en) 2012-02-23 2016-10-25 Bayer Intelletual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
WO2015193263A1 (en) * 2014-06-17 2015-12-23 Chiesi Farmaceutici S.P.A. Indolizine derivatives as phoshoinositide 3-kinases inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
CA3016196A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
SI3436461T1 (sl) 2016-03-28 2024-03-29 Incyte Corporation Pirolotriazinske spojine kot tam-inhibitorji
WO2018161033A1 (en) * 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
MX2019014875A (es) 2017-06-21 2021-01-29 SHY Therapeutics LLC Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
RS62872B1 (sr) 2017-09-27 2022-02-28 Incyte Corp Soli derivata pirrolotriazina korisne kao tam inhibitori
CN117771250A (zh) 2018-06-29 2024-03-29 因赛特公司 Axl/mer抑制剂的制剂
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
JP2022533570A (ja) 2019-05-13 2022-07-25 リレー セラピューティクス， インコーポレイテッド Ｆｇｆｒ阻害剤およびそれらの使用
AU2020355359B2 (en) * 2019-09-26 2023-08-24 Shenzhen Targetrx, Inc. Substituted aromatic fused ring derivative and composition comprising same, and use thereof
JP2023533771A (ja) * 2020-07-10 2023-08-04 ベイジン ファインドキュア バイオサイエンシーズ リミテッド トリアジン系化合物およびその組成物と用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60026297T2 (de) * 1999-05-21 2006-11-02 Bristol-Myers Squibb Co. Pyrrolotriazin kinasehemmer
CZ20031370A3 (cs) * 2000-11-17 2003-10-15 Bristol-Myers Squibb Company Způsob léčení stavů souvisejících s p38 kinázou a pyrrolotriazinové sloučeniny použitelné jako inhibitory kináz
WO2004013145A1 (en) * 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7405213B2 (en) 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2007064931A2 (en) 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
EP2203060A4 (en) 2007-09-25 2010-12-22 Bayer Healthcare Llc PYRROLOTRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER BY INHIBITING AURORA KINASE

Also Published As

Publication number Publication date
ATE462708T1 (de) 2010-04-15
ZA200700011B (en) 2008-11-26
US20070208013A1 (en) 2007-09-06
EP1765823B1 (en) 2010-03-31
SG127661A1 (en) 2007-01-30
US7563791B2 (en) 2009-07-21
SV2006002134A (es) 2006-10-04
HN2005000255A (es) 2010-09-17
AR049138A1 (es) 2006-06-28
MA28689B1 (fr) 2007-06-01
ECSP067043A (es) 2006-12-29
KR20070035028A (ko) 2007-03-29
US20130225809A1 (en) 2013-08-29
MY145077A (en) 2011-12-15
MX279139B (es) 2010-09-21
WO2005121147A1 (en) 2005-12-22
CA2569396A1 (en) 2005-12-22
RU2006147237A (ru) 2008-07-20
US20100075958A1 (en) 2010-03-25
MXPA06013457A (es) 2007-03-01
HK1109141A1 (en) 2008-05-30
PH12006502386B1 (en) 2010-12-23
DE602005020293D1 (de) 2010-05-12
CA2569396C (en) 2011-12-20
NO20070049L (no) 2007-01-30
AU2005252217A1 (en) 2005-12-22
UY28931A1 (es) 2005-12-30
CN1993361B (zh) 2010-05-26
JP2008501703A (ja) 2008-01-24
RU2401269C2 (ru) 2010-10-10
EP1765823A1 (en) 2007-03-28
IL179264A0 (en) 2007-03-08
PE20060243A1 (es) 2006-04-21
AU2005252217B2 (en) 2011-05-12
US8338595B2 (en) 2012-12-25
KR101235602B1 (ko) 2013-02-21
JP4958772B2 (ja) 2012-06-20
GT200500137A (es) 2006-05-18
TW200608979A (en) 2006-03-16
ES2342722T3 (es) 2010-07-13
NZ551742A (en) 2010-08-27
CN1993361A (zh) 2007-07-04

Similar Documents

Publication Publication Date Title
BRPI0510848A (pt) derivados de pirrolotriazina úteis para o tratamento de distúrbios e doenças hiperproliferativos associados com a angiogênese
DOP2006000269A (es) Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
BR0313733A (pt) Uso da proteìna n beta cinase
PA8543301A1 (es) Derivados de dihidro-benzo (b) (1,4) diazepin-2 -ona como antagonistas ii mglur2
BRPI0410170A (pt) preparação e uso de derivados de ácido aril alquìlico para o tratamento de obesidade
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
PA8543201A1 (es) DERIVADOS DE DIHIDRO-BENZO [B] [1,4]-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGluR2
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
BRPI0720178B8 (pt) derivados de 2,3-di-hidroimidazo[1,2-c]quinazolina substituída úteis para tratar distúrbios e doenças hiperproliferativos associados com angiogênese, e composições farmacêuticas
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
BRPI0618451A2 (pt) derivados de piridopirazina, seu uso, composição farmacêutica e estojo
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
ECSP055851A (es) Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
HN2006019068A (es) "sintesis de (r)-n-metilnaltrexona"
HN2008000311A (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
BRPI0511527A (pt) compostos e composições como moduladores de ppar
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
BR0206633A (pt) Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
BRPI0410986A (pt) derivados de estaurosporina para sìndrome hipereosinofìlica
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
BRPI0507157A (pt) uso de fator viia ou de um equivalente de fator viia, kit de partes para tratamento de trauma, e, métodos para tratar trauma e para prevenir, tratar trauma
HN2003000104A (es) Derivados de ciclopenteno

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER HEALTHCARE LLC (US)

Free format text: TRANSFERIDO DE: BAYER PHARMACEUTICALS CORPORATION

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.